Showing results (21-30 of 1,558) with videos related to
Sort By:
Pageof 156
Asia-Pacific Journal of Clinical Oncology|May 19, 2011
The impact of cytology screening and HPV vaccination on the burden of cervical cancerKaijun Tay, Sun K TayAsia-Pacific Journal of Clinical Oncology|May 19, 2011
Knowledge of Pap smear, HPV and the HPV vaccine and the acceptability of the HPV vaccine by Thai womenChuenkamon Charakorn, Sasivimol Rattanasiri, Arb-aroon Lertkhachonsuk, et al.Asia-Pacific Journal of Clinical Oncology|May 19, 2011
Zoledronic acid to prevent bone loss in Chinese men receiving androgen deprivation therapy for prostate cancerChi-hang Yee, Chi-fai Ng, Annie Y F Wong, et al.Asia-Pacific Journal of Clinical Oncology|December 14, 2011
Expression of telomere binding proteins in gastric cancer and correlation with clinicopathological parametersJinbo Gao, Jinghui Zhang, Yaoping Long, et al.Asia-Pacific Journal of Clinical Oncology|December 14, 2011
Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancerSumitra Thongprasert, Unchalee Permsuwan, Chidchanok Ruengorn, et al.Asia-Pacific Journal of Clinical Oncology|February 29, 2012
The role of magnetic resonance imaging in early breast cancerAnita R Skandarajah, G Bruce MannAsia-Pacific Journal of Clinical Oncology|February 29, 2012
Preoperative taxane-based chemotherapy in a standardized protocol for locally advanced breast cancerArlene Chan, Peter C Willsher, Diana J Hastrich, et al.Asia-Pacific Journal of Clinical Oncology|February 29, 2012
Quantification of trends in radiation oncology infrastructure in Pakistan, 2004-2009Naseem Begum, Shahida Nasreen, Abdul Saeed ShahAsia-Pacific Journal of Clinical Oncology|June 21, 2019
Pathological outcomes of HER2-positive non-metastatic breast cancer patients treated with neoadjuvant dual anti-HER2 therapy and taxane: An Australian experienceJoseph Do Woong Choi, Thomas Michael D Hughes, Gavin Marx, et al.Asia-Pacific Journal of Clinical Oncology|June 20, 2019
Cancer outcomes in patients requiring immunosuppression in addition to corticosteroids for immune-related adverse events after immune checkpoint inhibitor therapyNikki Burdett, Kristin Hsu, Libo Xiong, et al.Pageof 156